<DOC>
	<DOC>NCT00687284</DOC>
	<brief_summary>This study is conducted in Europe. An observational study evaluating glycaemic control in patients using Levemir® as initiation insulin therapy as the treatment of type 2 diabetes in Slovakia.</brief_summary>
	<brief_title>Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Patients with type 2 diabetes Patients inadequately controlled by OAD Patients willing to sign informed consent Selection of study participants at the discretion of the physician Particular attention should be paid to the drug interactions that are listed within the product label Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for the final visit; Subjects who were previously enrolled in this study Subjects with a hypersensitivity to insulin detemir or to any of the excipients. Women who are pregnant, breastfeeding or have the intention of becoming pregnant within next 6 months</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>